Neuroendocrine carcinoma and Weakness

Summary:

Weakness is found among people with Neuroendocrine carcinoma, especially for people who are female, 60+ old.

The study analyzes which people have Weakness with Neuroendocrine carcinoma. It is created by eHealthMe based on reports of 215 people who have Neuroendocrine carcinoma from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Neuroendocrine carcinoma?

Neuroendocrine carcinoma (cancer tumour that arise from cells of the endocrine (hormonal) and nervous systems) is found to be associated with 119 drugs and 190 conditions by eHealthMe. Check the latest studies of Neuroendocrine carcinoma.

What is Weakness?

Weakness is found to be associated with 3,640 drugs and 6,613 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 08, 2026

215 people who have Neuroendocrine Carcinoma and Weakness are studied.

Would you have Weakness when you have Neuroendocrine carcinoma?

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Weakness?

- Check whether Weakness is associated with a drug or a condition

Related studies:

Treatments, associated drugs and conditions:

Neuroendocrine carcinoma (3,065 reports)
Weakness (586,876 reports)

All the drugs that are associated with Weakness:

Weakness (3,640 drugs)

All the conditions that are associated with Weakness:

Weakness (6,613 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Weakness and Neuroendocrine carcinoma, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Neuroendocrine carcinoma and Weakness

Summary:

What is Neuroendocrine carcinoma?

What is Weakness?

Gender of people who have Neuroendocrine carcinoma and experienced Weakness *:

Age of people who have Neuroendocrine carcinoma and experienced Weakness *:

Common co-existing conditions for these people *:

Common drugs taken by these people *:

Common symptoms for these people *: